# Constipation on a GLP-1: What the Labels Report and What Actually Helps

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-18 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1-constipation-what-works

> The Wegovy label reports constipation in 24% against 11% on placebo; the Zepbound label reports it by dose. This explains why it outlasts the nausea and where the confident advice online runs ahead of the evidence.

## Key points

- Wegovy label: constipation in 24% against 11% on placebo (Section 6.1).
- Zepbound label reports it by dose: 17% at 5 mg, 14% at 10 mg, 11% at 15 mg, against 5%.
- It outlasts nausea: a median 47 days per episode on semaglutide in STEP, against 35 on placebo, though it eases over time.
- Severe pain with vomiting and no passage of gas is bowel obstruction, not constipation, and it is an emergency.

Constipation is not a sign the drug is going wrong. It ranks among the most frequent GLP-1 side effects, and it usually lingers longer than the others. The Wegovy label reports it in **24%** of patients against 11% on placebo, and the Zepbound label reports it by dose: 17% at 5 mg, 14% at 10 mg, 11% at 15 mg, against 5%.[1][2] Below is what the evidence supports doing about it, and where the confident advice online runs ahead of what anyone has shown.

## Why it happens, and why it does not fade like nausea

The labels say these drugs [delay stomach emptying](https://glpwatchdog.org/research/ozempic-stomach-paralysis-gastroparesis), and slower movement through the gut is the usual explanation for constipation: the longer stool takes to pass, the more water is drawn out of it. That explanation is plausible rather than proven. The authors of the pooled STEP analysis describe the cause of the stomach side effects as uncertain, note that the longer-acting drugs do not appear to delay emptying much, and point to a 20-week study of semaglutide 2.4 mg that found no measurable delay.[6]

What is well established is that constipation behaves differently from nausea. Nausea is worst in the opening weeks and at each dose increase, then settles. Constipation lasts longer: in the pooled STEP trials the median episode ran 47 days on semaglutide against 35 on placebo, compared with 2 or 3 days for vomiting and diarrhea. It does ease with time, though. In STEP 4, where people stayed on semaglutide for more than a year, constipation became less common as the months went on.[6] Our [side-effect timeline](https://glpwatchdog.org/tools/glp1-side-effect-timeline) shows the two curves side by side for each drug. Diarrhea, the opposite complaint on the same drugs, behaves differently again and has no settled explanation; see [GLP-1 diarrhea: what has actually been tested](https://glpwatchdog.org/research/glp1-diarrhea-what-helps).

There is a second cause that gets less attention, and it may matter more. Appetite suppression means eating less, and eating less usually means less fiber and less fluid. Some of what people experience as a drug effect is a diet effect the drug caused indirectly. The distinction matters because the diet effect is the one you can fix directly.

## What the labels actually report

*Constipation as reported in Section 6.1 of each FDA label. Figures verified against DailyMed on May 23, 2026.*

| Drug | Reported rate | Placebo |
| --- | --- | --- |
| Wegovy (semaglutide 2.4 mg)[1] | 24% | 11% |
| Zepbound (tirzepatide)[2] | 17% at 5 mg, 14% at 10 mg, 11% at 15 mg | 5% |
| Saxenda (liraglutide 3 mg)[3] | 19.4% | 8.5% |

> **Correction, September 11, 2026.** This table previously showed no placebo figure for Saxenda; the label gives 8.5%.[3] This box also explained Zepbound’s falling rate, 17% at 5 mg down to 11% at 15 mg, as people who could not tolerate the climb dropping out of the top-dose column. That was wrong. Each column is a group randomized to that dose,[2] and SURMOUNT-1, one of the two trials behind the table, analyzed safety by the group people were randomized to, regardless of the treatment they actually received.[8] The label does not explain the pattern, and neither do we.

## How common the serious end is

A 2023 analysis in JAMA looked at gastrointestinal adverse events among people taking GLP-1 medicines for weight loss rather than diabetes, and found elevated rates of outcomes that matter more than discomfort, among them bowel obstruction.[4] The absolute numbers were small, and the detail matters: the semaglutide group in that study had no obstruction events at all, the signal came from liraglutide, and the result lost statistical significance in one of the authors’ own re-analyses.[4] A 2025 pooling of 55 placebo-controlled trials concluded the drugs likely make little or no difference to the risk of obstruction or ileus.[7] That is reassuring, but it is not a reason to ignore the warning signs below.

A 2026 comparative study in the Annals of Internal Medicine set dulaglutide, semaglutide and tirzepatide against each other on gastrointestinal safety in type 2 diabetes.[5] Comparative work of that kind is what tells you whether switching drugs is a plausible answer to a gut problem, which is a question a great many people ask and very few sources answer with evidence.

> Constipation that has become severe abdominal pain, persistent vomiting, or an inability to pass gas is not a fiber problem. That combination is how [bowel obstruction](https://glpwatchdog.org/research/glp1-bowel-obstruction-and-ileus) presents, and it is an emergency department visit rather than a pharmacy one. Nothing on this page applies to it. For stomach pain more generally, [GLP-1 stomach pain: what is expected and what is a warning sign](https://glpwatchdog.org/research/glp1-stomach-pain-when-to-worry) sets out the patterns the labels single out.

## What the evidence supports trying

This has been studied far less than the confident advice suggests. The steps below run from the best supported to the least.

1. **Put back the fiber the appetite suppression removed.** This is the best-founded step, and it works as a correction: you are restoring an intake the drug quietly cut. Our [fiber calculator](https://glpwatchdog.org/tools/glp1-fiber-calculator) works the target from the National Academies figures and steps you up about 5 g a week, because arriving at a high-fiber diet in one jump produces bloating and gas on top of everything else. A [low-FODMAP diet](https://glpwatchdog.org/research/low-fodmap-diet-on-a-glp1) pulls the other way, cutting whole grains and beans, so it needs fiber added back.
2. **Water alongside it, not instead of it.** Fiber without fluid makes stool bulkier and harder, which is the opposite of the goal. This is the step most often given alone and it is the one least likely to work alone.
3. **Movement.** Weakly supported for constipation generally, and worth doing for other reasons regardless.
4. **Anything pharmacological is a prescriber conversation.** Osmotic laxatives, stool softeners and stimulant laxatives are different drugs doing different things, some of which interact with how you are already taking a GLP-1. We are not going to name one.

What we could not find is good evidence on the question people most want answered: whether any of this works *specifically* for drug-induced slowed transit, as opposed to constipation in general. The guidance being applied is largely general-population guidance borrowed for a new situation. That is reasonable, but it has not been tested here. A 2026 systematic review of randomized trials of dietary strategies alongside these drugs reached the same conclusion: stomach symptoms happened anyway, and the evidence on the best nutritional approach remains limited.[9]

## When the answer is the dose

Holding a dose longer before stepping up, or dropping back a step, is a real option and a common one. It is also entirely your prescriber’s to make. The labels build “as tolerated” language into the titration schedule precisely so a clinician can use it.

If that is the conversation you are heading into, go in with specifics: which dose you are on, how long you have been on it, how many days without a movement, and what you have already tried. Our [titration planner](https://glpwatchdog.org/tools/glp1-titration-planner) will print the schedule from your drug’s own label so you can point at the step you are standing on.

## Frequently asked questions

### Is constipation on a GLP-1 normal?

It is common enough to appear in the adverse reactions table of every label. The Wegovy label reports 24% against 11% on placebo; the Zepbound label reports 17% at 5 mg, 14% at 10 mg and 11% at 15 mg against 5%.

### Does it go away like the nausea does?

Not as quickly. Nausea is worst early and at each dose increase, then settles. Constipation lasts longer: in the pooled STEP trials the median episode ran 47 days on semaglutide against 35 on placebo. It does ease with time, though. In STEP 4 it became less common as the months went on.

### Will fiber fix it?

Fiber is the best-supported first step, but it is more accurate to call it a correction than a cure. Eating less on a GLP-1 usually means eating less fiber, so part of what you are doing is restoring what the appetite suppression removed. Increase gradually, and drink more water alongside it rather than instead of it.

### When is constipation an emergency?

Severe abdominal pain, persistent vomiting, or being unable to pass gas together suggest bowel obstruction rather than ordinary constipation. That is an emergency department presentation, not something to manage at home.

### Should I lower my dose?

That is a decision for the clinician who prescribed it. The labels deliberately include as-tolerated language in the titration schedule so a prescriber can hold a dose longer or step back, but it is their judgment to apply, not a chart's.

## References

1. Novo Nordisk Inc. WEGOVY (semaglutide) injection — US Prescribing Information, Section 6.1 Adverse Reactions. DailyMed (FDA-approved labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Section 6.1 Adverse Reactions. DailyMed (FDA-approved labeling). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3. Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information, Section 6.1 Adverse Reactions. DailyMed (FDA-approved labeling). 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
4. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023. PMID: 37796527. https://pubmed.ncbi.nlm.nih.gov/37796527/
5. Crisafulli S, Alkabbani W, Paik JM, et al. Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. Annals of Internal Medicine. 2026. PMID: 41183330. https://pubmed.ncbi.nlm.nih.gov/41183330/
6. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism. 2022. PMID: 34514682. https://pubmed.ncbi.nlm.nih.gov/34514682/
7. Chiang CH, Jaroenlapnopparat A, Colak SC, et al. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis. Gastroenterology. 2025. PMID: 40499738. https://pubmed.ncbi.nlm.nih.gov/40499738/
8. Eli Lilly and Company A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) — results record, adverse events (NCT04184622). ClinicalTrials.gov. 2026. https://clinicaltrials.gov/study/NCT04184622?tab=results
9. de Paulo RS, Bonifácio DB, de Carvalho MHL, et al. Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials. Diabetes, Obesity and Metabolism. 2026. PMID: 42037117. https://pubmed.ncbi.nlm.nih.gov/42037117/

---

Cite as: GLP Watchdog, Ruth Calder, "Constipation on a GLP-1: What the Labels Report and What Actually Helps", published 2026-08-18, updated 2026-10-27. https://glpwatchdog.org/research/glp1-constipation-what-works

Canonical HTML page: https://glpwatchdog.org/research/glp1-constipation-what-works

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
